Who are the top shareholders of the Syngene Intl.?

The top shareholders of Syngene International are Biocon Limited with 52.46%, mutual funds at 17.86%, and foreign institutional investors holding 19.47%. The highest public shareholder is ICICI Prudential Innovation Fund with a 5.13% stake, while individual investors own about 5.08%.

The top shareholders of Syngene International include Biocon Limited, which holds the largest stake at 52.46%. Other significant shareholders are mutual funds, which collectively own 17.86% of the company, and foreign institutional investors (FIIs) who hold 19.47%. The highest public shareholder is ICICI Prudential Innovation Fund, with a 5.13% stake. Additionally, individual investors own about 5.08% of the shares.

When is the next results date for Syngene Intl.?

No Upcoming Board Meetings

Who are in the management team of Syngene Intl.?

As of March 2022, the management team of Syngene International includes Kiran Mazumdar Shaw (Chairperson), Jonathan Hunt (Managing Director & CEO), and several independent directors, bringing diverse expertise to the company.

As of March 2022, the management team of Syngene International includes:<BR><BR>1. Kiran Mazumdar Shaw - Chairperson<BR>2. Catherine Patricia Rosenberg - Director<BR>3. Paul Frederick Blackburn - Independent Director<BR>4. Vijay Kuchroo - Independent Director<BR>5. Jonathan Hunt - Managing Director & CEO<BR>6. Vinita Bali - Lead Independent Director<BR>7. Priyadarshnini Mahapatra - Company Secretary & Compliance Officer<BR>8. Sharmila Karve - Independent Director<BR>9. Carl Decicco - Director<BR>10. Kush Parmar - Independent Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

What does Syngene Intl. do?

Syngene International Limited is a large-cap integrated research, development, and manufacturing services organization in the healthcare sector, with recent net sales of ₹1,018 Cr and a net profit of ₹183 Cr for the quarter ending March 2025. The company has a market cap of ₹26,022 Cr and key metrics include a P/E ratio of 55.00 and a dividend yield of 0.19%.

Overview:<BR>Syngene International Limited is an integrated research, development, and manufacturing services organization operating in the healthcare services industry and classified as a large-cap company.<BR><BR>History:<BR>Syngene International was incorporated in an unspecified year and has maintained its status as a leading service provider in the healthcare sector. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1,018 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 183 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 26,022 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 55.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.19% <BR>Debt-Equity: -0.17 <BR>Return on Equity: 9.99% <BR>Price-to-Book: 5.52 <BR><BR>Contact Details:<BR>Address: Biocon SEZ Biocon Park, Plot No 2 & 3 Bommasandra Inds Bengaluru Karnataka : 560099 <BR>Phone: 91-80-68915000/67758781 <BR>Email: investor@syngeneintl.com <BR>Website: http://www.syngeneintl.com

What is the bonus history of the Syngene Intl.?

Syngene International Ltd announced a 1:1 bonus issue on June 11, 2019, with a record date of June 12, 2019, allowing shareholders to receive one additional share for each share held.

Syngene International Ltd has a bonus history that includes a 1:1 bonus issue announced on June 11, 2019. The record date for this bonus was June 12, 2019. This means that shareholders received one additional share for every share they held as of the record date.

Has Syngene Intl. declared dividend?

Syngene International Ltd has declared a dividend of 12% (₹1.2 per share) with an ex-date of June 28, 2024. While recent total returns have been negative, longer-term performance shows positive growth.

Syngene International Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 12%<BR>- Amount per share: 1.2<BR>- Ex-date: Jun-28-2024<BR><BR>Dividend Yield: 0.19%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -30.02%, the dividend return was 0.14%, resulting in a total return of -29.88%.<BR><BR>Over the past year, the price return was -5.96%, the dividend return was 0.34%, leading to a total return of -5.62%.<BR><BR>For the 2-year period, the price return was -12.31%, the dividend return was 0.42%, culminating in a total return of -11.89%.<BR><BR>In the last 3 years, the price return was 20.73%, the dividend return was 0.65%, resulting in a total return of 21.38%.<BR><BR>Over the past 4 years, the price return was 9.33%, the dividend return was 0.62%, leading to a total return of 9.95%.<BR><BR>In the 5-year period, the price return was 74.97%, the dividend return was 0.89%, culminating in a total return of 75.86%.<BR><BR>Overall, while Syngene International Ltd has declared a dividend, the total returns over various periods show a mixed performance, with significant declines in the short term but positive returns over the longer term.

Who are the peers of the Syngene Intl.?

Syngene Intl.'s peers include Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Health, Thyrocare Tech., Suven Life Sciences, Laxmi Dental, and Vimta Labs. Syngene has good management risk but below-average growth and the lowest 1-year return among its peers at -3.62%.

Peers: The peers of Syngene Intl. are Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Suven Life Scie., Laxmi Dental, and Vimta Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Laxmi Dental, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Vimta Labs, and the rest. Below Average management risk is noted at Suven Life Scie. and Average management risk is found at Krsnaa Diagnost. Growth is Good at Laxmi Dental, Average at Poly Medicure, Indegene, and Vimta Labs, while Below Average growth is observed at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and the rest, with Suven Life Scie. showing Below Average growth. Excellent capital structure is seen at Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Krsnaa Diagnost., while Good capital structure is noted at Laxmi Dental, and Below Average at Suven Life Scie.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 160.99%, while the lowest is Syngene Intl. at -3.62%. Syngene Intl.'s 1-year return is lower than that of all its peers. Additionally, the six-month return is negative for Syngene Intl., Poly Medicure, Vijaya Diagnost., Metropolis Healt, and Krsnaa Diagnost.

How big is Syngene Intl.?

As of 24th July, Syngene International Ltd has a market capitalization of 26,910.00 Cr, with recent net sales of 3,727.20 Cr and a net profit of 507.20 Cr.

As of 24th July, Syngene International Ltd has a market capitalization of 26,910.00 Cr, categorizing it as a Large Cap company.<BR><BR>In the latest four quarters, Syngene reported Net Sales of 3,727.20 Cr and a Net Profit of 507.20 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 4,726.80 Cr and Total Assets of 6,766.50 Cr.

Are Syngene Intl. latest results good or bad?

Syngene International's latest results are concerning, with a 36.76% decline in net profit despite a 2.20% revenue increase, indicating operational inefficiencies and pricing pressures. The stock reacted negatively, reflecting poor profitability metrics and raising questions about the company's competitive positioning.

Syngene International's latest results indicate a challenging situation for the company. While revenue showed a slight increase of 2.20% year-on-year, net profit experienced a significant decline of 36.76%, dropping to ₹67.10 crores. This decline in profitability is concerning, especially as it marks the lowest quarterly profit since June 2024, excluding seasonal variations.<BR><BR>The operating margin has also compressed to 21.91%, which is the lowest in the past eight quarters, reflecting operational inefficiencies and potential pricing pressures. Additionally, the profit after tax margin fell to 7.37%, down from 11.91% a year ago, indicating further deterioration in profitability metrics.<BR><BR>Despite a modest revenue growth, the disconnect between revenue and profit growth raises questions about the company's operational model and competitive positioning. The stock has reacted negatively to these results, declining by 2.87% following the announcement, contributing to a year-to-date loss of 30.76%.<BR><BR>In summary, the results can be characterized as poor, with significant declines in profitability and concerns over operational efficiency, which may challenge the company's premium valuation in the market.

How has been the historical performance of Syngene Intl.?

Syngene Intl. has shown consistent growth in net sales and operating profit from INR 1,825.60 crore in March 2019 to INR 3,642.40 crore in March 2025, although profit after tax slightly declined in 2025. Total assets and cash flow from operations have also improved significantly during this period.

Answer:<BR>The historical performance of Syngene Intl. shows a consistent growth trajectory in net sales and profits over the years.<BR><BR>Breakdown:<BR>Syngene Intl. has demonstrated a strong upward trend in net sales, increasing from INR 1,825.60 crore in March 2019 to INR 3,642.40 crore in March 2025. This growth is reflected in the total operating income, which also rose from INR 1,825.60 crore to INR 3,642.40 crore during the same period. The company's operating profit (PBDIT) has similarly improved, reaching INR 1,113.60 crore in March 2025, up from INR 611.90 crore in March 2019. However, profit after tax showed a slight decline from INR 510.00 crore in March 2024 to INR 496.20 crore in March 2025. The total assets of Syngene increased significantly from INR 4,040.20 crore in March 2020 to INR 6,766.50 crore in March 2025, while total liabilities also rose from INR 4,040.20 crore to INR 6,766.50 crore in the same timeframe. Cash flow from operating activities has improved, reaching INR 1,167.00 crore in March 2025, compared to INR 677.00 crore in March 2020, indicating a positive cash generation trend. Overall, Syngene Intl. has shown robust growth in revenue and operational efficiency, despite some fluctuations in net profit.

Is Syngene Intl. technically bullish or bearish?

As of December 2, 2025, Syngene Intl. has shifted to a bearish technical stance, indicated by negative signals from moving averages, Bollinger Bands, MACD, and KST across multiple time frames.

As of 2 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Syngene Intl. is bearish with a moderate strength. Key indicators driving this stance include the bearish signals from the moving averages on the daily chart, the bearish readings from the Bollinger Bands on both weekly and monthly time frames, and the bearish MACD on the monthly chart. Additionally, the KST is bearish on both weekly and monthly time frames, reinforcing the bearish outlook. The lack of trend signals in Dow Theory and OBV further supports the bearish sentiment.

Which are the latest news on Syngene Intl.?

Should I buy, sell or hold Syngene Intl.?

Why is Syngene Intl. falling/rising?

As of 03-Dec, Syngene International Ltd's stock price is slightly rising at 636.60, following two days of decline, but it has a year-to-date drop of 25.86% and negative quarterly earnings. Despite today's uptick, the stock faces ongoing challenges and is considered overvalued compared to peers.

As of 03-Dec, Syngene International Ltd's stock price is experiencing a slight rise, currently at 636.60, with a change of 0.65 (0.1%) upward. This increase follows a trend reversal after two consecutive days of decline. The stock's performance today is reported to be in line with the sector, and there has been a notable rise in investor participation, with a delivery volume increase of 35.03% compared to the 5-day average.<BR><BR>Despite this short-term uptick, the stock has shown poor long-term growth, with a year-to-date decline of 25.86% and a one-year drop of 31.87%. The company has reported negative results in its latest quarterly earnings, with significant declines in both profit before tax and profit after tax compared to previous quarters. Additionally, the stock is trading at a premium valuation with a Price to Book Value of 5.4, which is considered expensive relative to its peers.<BR><BR>Overall, while there is a minor rise in the stock price today, the broader context indicates ongoing challenges, including underperformance in both short-term and long-term metrics, which may continue to affect investor sentiment negatively.